Applied Therapeutics, Inc. (APLT): Price and Financial Metrics

Applied Therapeutics, Inc. (APLT): $5.05

0.21 (-3.99%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add APLT to Watchlist
Sign Up

APLT Price/Volume Stats

Current price $5.05 52-week high $9.39
Prev. close $5.26 52-week low $1.18
Day low $4.93 Volume 672,400
Day high $5.28 Avg. volume 1,549,930
50-day MA $4.64 Dividend yield N/A
200-day MA $3.66 Market Cap 577.05M

APLT Stock Price Chart Interactive Chart >


Applied Therapeutics, Inc. (APLT) Company Bio


Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY


APLT Latest News Stream


Event/Time News Detail
Loading, please wait...

APLT Latest Social Stream


Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about APPLIED THERAPEUTICS INC that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!

William White on InvestorPlace | December 19, 2023

Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ...

Regulatory Submissions and Phase 3 Trials in Focus

Yahoo | November 9, 2023

Applied Therapeutics Reports Third Quarter 2023 Financial Results

Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol Dehydrogenase (SORD) Deficiency in 1Q 2024 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developin

Yahoo | November 9, 2023

Applied Therapeutics, Inc. (NASDAQ:APLT) is definitely on the radar of institutional investors who own 38% of the company

Key Insights Institutions' substantial holdings in Applied Therapeutics implies that they have significant influence...

Yahoo | November 5, 2023

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the UBS Biopharma Conference 2023 on Thursday, November 9, 2023 at 2:00 p.m. ET in Miami, Florida. A live webcast for this event will be accessible on the Events page under the Investor Relations section

Yahoo | November 2, 2023

Read More 'APLT' Stories Here

APLT Price Returns

1-mo 20.53%
3-mo -19.33%
6-mo 70.61%
1-year 234.44%
3-year -77.50%
5-year -45.46%
YTD 50.75%
2023 340.79%
2022 -91.51%
2021 -59.34%
2020 -19.32%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!